|
1.
|
|
11 p, 379.4 KB |
Postoperative Chemotherapy Use and Outcomes From ADAURA : Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
/
Wu, Yi-Long (Guangdong Lung Cancer Institute) ;
John, Thomas (Austin Health) ;
Grohe, Christian (Evangelische Lungenklinik) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Goldman, Jonathan W. (University of California) ;
Kim, Sang-We (University of Ulsan) ;
Kato, Terufumi (Kanagawa Cancer Center) ;
Laktionov, Konstantin (Blokhin National Medical Research Center of Oncology) ;
Vu, Huu Vinh (Choray Hospital) ;
Wang, Zhije (Chinese Academy of Medical Sciences) ;
Lu, Shun (Shanghai Jiao Tong University) ;
Lee, Kye Young (Konkuk University Medical Center) ;
Akewanlop, Charuwan (Siriraj Hospital) ;
Yu, Chong-Jen (National Taiwan University College of Medicine) ;
de Marinis, Filippo (European Institute of Oncology) ;
Bonanno, Laura (Istituto Oncologico Veneto) ;
Domine, Manuel (Instituto de Investigación Sanitaria-Fundación Jiménez Díaz) ;
Shepherd, Frances A. (University of Toronto) ;
Zeng, Lingmin (AstraZeneca) ;
Atasoy, Ajlan (AstraZeneca) ;
Herbst, Roy S. (Yale School of Medicine) ;
Tsuboi, Masahiro (National Cancer Center Hospital East) ;
Universitat Autònoma de Barcelona
Introduction: Adjuvant chemotherapy is recommended in patients with resected stages II to IIIA (and select IB) NSCLC; however, recurrence rates are high. In the phase 3 ADAURA study (NCT02511106), osimertinib was found to have a clinically meaningful improvement in disease-free survival (DFS) in patients with resected stages IB to IIIA EGFR-mutated (EGFRm) NSCLC. [...]
2022 -  10.1016/j.jtho.2021.10.014
Journal of Thoracic Oncology, Vol. 17 Núm. 3 (march 2022) , p. 423-433
|
|
|
2.
|
|
11 p, 421.8 KB |
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
/
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Goldman, Jonathan W. (David Geffen School of Medicine. University of California Los Angeles) ;
John, Thomas (Department of Medical Oncology. Austin Health) ;
Grohe, Christian (Klinik fur € Pneumologie-Evangelische Lungenklinik Berlin Buch) ;
Laktionov, Konstantin (N.N. Blokhin National Medical Research Center of Oncology (Rússia)) ;
Kim, Sang-We (Department of Oncology. Asan Medical Center) ;
Kato, Terufumi (Depart-ment of Thoracic Oncology. Kanagawa Cancer Center) ;
Vu, Huu Vinh (Department of Thoracic Surgery. Choray Hospital) ;
Lu, Shun (Lung Cancer Center. Shanghai Chest Hospital. Shanghai Jiao Tong University) ;
Li, Shanqing (Department of Thoracic Surgery. Peking Union Medical College Hospital. Chinese Academy of Medical Sciences) ;
Lee, Kye Young (Pre-cision Medicine Lung Cancer Center. Konkuk University Medical Center) ;
Akewanlop, Charuwan (Division of Medical Oncology. Faculty of Medicine. Siriraj Hospital) ;
Yu, Chong-Jen (Department of Internal Medicine. National Taiwan University Hospital Hsinchu Branch. National Taiwan University College of Medicine) ;
De Marinis, Filippo (Thoracic Oncology Division. European Institute of Oncology (IEO). IRCCS) ;
Bonanno, Laura (Medical Oncology 2. Istituto Oncologico Veneto (IOV). IRCCS) ;
Domine, Manuel (Hospital Universitario Fundacion Jimenez Díaz. Servicio de Oncología) ;
Shepherd, Frances A. (Department of Medical Oncology and Hematology. University Health Network. Princess Margaret Cancer Center. the University of Toronto) ;
Atagi, Shinji (Department of Thoracic Oncology. National Hospital Organization Kinki-Chuo Chest Medical Center) ;
Zeng, Lingmin (Late Oncology Statistics. AstraZeneca) ;
Kulkarni, Dakshayini (Late Oncology R&D. AstraZeneca) ;
Medic, Nenad (AstraZeneca Oncology Business Unit. Academy House) ;
Tsuboi, Masahiro (Department of Thoracic Surgery and Oncology. National Cancer Center Hospital East) ;
Herbst, Roy S. (Medical Oncology. Yale School of Medicine. Yale Cancer Center) ;
Wu, Yi-Long (Guangdong Lung Cancer Institute)
Purpose: In the phase III ADAURA trial, adjuvant treatment with osimertinib versus placebo, with/without prior adjuvant chemotherapy, resulted in a statistically significant and clinically meaningful disease-free survival benefit in completely resected stage IB-IIIA EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). [...]
2022 - 10.1158/1078-0432.CCR-21-3530
Clinical Cancer Research, Vol. 28 Núm. 11 (january 2022) , p. 2286-2296
|
|
|
3.
|
|
7 p, 525.4 KB |
Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma
/
Shiraishi, Kouya (National Cancer Center Research Institute (Tòquio, Japó)) ;
Okada, Yukinori (Tokyo Medical and Dental University) ;
Takahashi, Atsushi (RIKEN Center for Integrative Medical Sciences (Yokohama, Japó)) ;
Kamatani, Yoichiro (RIKEN Center for Integrative Medical Sciences (Yokohama, Japó)) ;
Momozawa, Yukihide (RIKEN Center for Integrative Medical Sciences (Yokohama, Japó)) ;
Ashikawa, Kyota (RIKEN Center for Integrative Medical Sciences (Yokohama, Japó)) ;
Kunitoh, Hideo (Japanese Red Cross Medical Center (Tòquio, Japó)) ;
Matsumoto, Shingo (National Cancer Center Research Institute (Tòquio, Japó)) ;
Takano, Atsushi (The University of Tokyo) ;
Shimizu, Kimihiro (Gunma University Hospital (Maebashi, Japó)) ;
Goto, Akiteru (Akita University (Akita, Japó)) ;
Tsuta, Koji (National Cancer Center Hospital (Tòquio, Japó)) ;
Watanabe, Shun-ichi (National Cancer Center Hospital (Tòquio, Japó)) ;
Ohe, Yuichiro (National Cancer Center Hospital (Tòquio, Japó)) ;
Watanabe, Yukio (National Cancer Center Hospital (Tòquio, Japó)) ;
Goto, Yasushi (National Cancer Center Hospital (Tòquio, Japó)) ;
Nokihara, Hiroshi (National Cancer Center Hospital (Tòquio, Japó)) ;
Furuta, Koh (National Cancer Center Hospital (Tòquio, Japó)) ;
Yoshida, Akihiko (National Cancer Center Hospital (Tòquio, Japó)) ;
Goto, Koichi (National Cancer Center Hospital East (Chiba, Japó)) ;
Hishida, Tomoyuki (National Cancer Center Hospital East (Chiba, Japó)) ;
Tsuboi, Masahiro (National Cancer Center Hospital East (Chiba, Japó)) ;
Tsuchihara, Katsuya (National Cancer Center Research Institute (Tòquio, Japó)) ;
Miyagi, Yohei (Kanagawa Cancer Center Research Institute (Yokohama, Japó)) ;
Nakayama, Haruhiko (Kanagawa Cancer Center (Yokohama, Japó)) ;
Yokose, Tomoyuki (Kanagawa Cancer Center (Yokohama, Japó)) ;
Tanaka, Kazumi (Gunma University Hospital (Maebashi, Japó)) ;
Nagashima, Toshiteru (Gunma University Hospital (Maebashi, Japó)) ;
Ohtaki, Yoichi (Gunma University Hospital (Maebashi, Japó)) ;
Maeda, Daichi (Akita University (Akita, Japó)) ;
Imai, Kazuhiro (Akita University (Akita, Japó)) ;
Minamiya, Yoshihiro (Akita University (Akita, Japó)) ;
Sakamoto, Hiromi (National Cancer Center Research Institute (Tòquio, Japó)) ;
Saito, Akira (StaGen Co., Ltd. (Tòquio, Japó)) ;
Shimada, Yoko (National Cancer Center Research Institute (Tòquio, Japó)) ;
Sunami, Kuniko (National Cancer Center Research Institute (Tòquio, Japó)) ;
Saito, Motonobu (National Cancer Center Research Institute (Tòquio, Japó)) ;
Inazawa, Johji (Tokyo Medical and Dental University) ;
Nakamura, Yusuke (University of Chicago) ;
Yoshida, Teruhiko (National Cancer Center Research Institute (Tòquio, Japó)) ;
Yokota, Jun (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ;
Matsuda, Fumihiko (Kyoto University) ;
Matsuo, Keitaro (Aichi Cancer Center Research Institute (Nagoya, Japó)) ;
Daigo, Yataro (The University of Tokyo) ;
Kubo, Michiaki (RIKEN Center for Integrative Medical Sciences (Yokohama, Japó)) ;
Kohno, Takashi (National Cancer Center Research Institute (Tòquio, Japó))
Lung adenocarcinoma driven by somatic EGFR mutations is more prevalent in East Asians (30-50%) than in European/Americans (10-20%). Here we investigate genetic factors underlying the risk of this disease by conducting a genome-wide association study, followed by two validation studies, in 3,173 Japanese patients with EGFR mutation-positive lung adenocarcinoma and 15,158 controls. [...]
2016 - 10.1038/ncomms12451
Nature communications, Vol. 7 (August 2016) , art. 12451
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
